The use of highly active molecules for Huntington's Disease therapy requires regulation of gene expression to avoid toxicity. GeneSwitch-regulated GDNF and miHtt expression will be tested Safety and efficacy of AAV5-delivered molecules will be evaluated in rodent HD models and marmoset brains.
Participating countries >SWITZERLAND,GERMANY,THE NETHERLANDS,POLAND
(bron: www.eurekanetwork.org/project-search)
